Growth & profitability
- Revenue has grown 1388.7% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
IOVA Financials Iovance Biotherapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $264M | -$391M | 34.3% | -153.1% | -$336M | — | $163M |
| 2024 | $164M | -$372M | 43.2% | -240.9% | -$364M | — | $116M |
| 2023 | $1M | -$444M | 13.1% | -38735.0% | -$384M | — | $115M |
| 2022 | — | -$396M | — | — | -$313M | — | $232M |
| 2021 | — | -$342M | — | — | -$266M | — | $78M |
| 2020 | — | -$260M | — | — | -$252M | — | $67M |
| 2019 | — | -$198M | — | — | -$166M | — | $14M |
| 2018 | — | -$124M | — | — | -$102M | — | $82M |
| 2017 | — | -$92M | — | — | -$80M | — | $145M |
| 2016 | — | -$53M | — | — | -$34M | — | $107M |
| 2015 | — | -$28M | — | — | -$20M | — | $34M |
| 2014 | — | -$12M | — | — | $7M | — | $45M |
| 2014 | — | -$58M | — | — | -$15M | — | $18M |
| 2013 | — | -$25M | — | — | -$4M | — | $20M |
| 2013 | — | -$45M | — | — | -$11M | — | $129804 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $71M | -$79M | 40.5% | -113.5% | -$79M | — | $197M |
| Dec '25 | $87M | -$72M | 50.3% | -84.7% | -$62M | — | $163M |
| Sep '25 | $67M | -$91M | 43.0% | -140.7% | -$90M | — | $158M |
| Jun '25 | $60M | -$112M | 5.5% | -189.8% | -$75M | — | $132M |
| Mar '25 | $49M | -$116M | 13.4% | -245.8% | -$110M | — | $172M |
| Dec '24 | $74M | -$79M | 48.7% | -117.5% | -$77M | — | $116M |
| Sep '24 | $59M | -$84M | 46.2% | -152.1% | -$61M | — | $164M |
| Jun '24 | $31M | -$97M | -0.8% | -327.6% | -$99M | — | $229M |
| Mar '24 | $715000 | -$113M | -915.5% | -16464.6% | -$126M | — | $134M |
| Dec '23 | $482000 | -$116M | -805.6% | -25156.8% | -$87M | — | $115M |
| Sep '23 | $469000 | -$114M | -825.4% | -25236.9% | -$88M | — | $268M |
| Jun '23 | $238000 | -$107M | -761.3% | -46254.6% | -$103M | — | $230M |
| Mar '23 | — | -$107M | — | — | -$105M | — | $543M |
| Dec '22 | — | -$105M | — | — | -$81M | — | $232M |
| Sep '22 | — | -$100M | — | — | -$65M | — | $118M |
| Jun '22 | — | -$99M | — | — | -$82M | — | $108M |
| Mar '22 | — | -$92M | — | — | -$85M | — | $92M |
| Dec '21 | — | -$99M | — | — | -$61M | — | $78M |
| Sep '21 | — | -$86M | — | — | -$67M | — | $59M |
| Jun '21 | — | -$81M | — | — | -$64M | — | $83M |
Valuation over time
How the market has priced IOVA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 2899.1× (Jan '24) to 7.1× (Jun '26).
P/S
Frequently asked questions
Is IOVA growing its revenue and profit?
Over the past 5 years, Iovance Biotherapeutics, Inc.'s revenue has grown 1388.7% per year. These are computed facts, not advice.
How much debt does IOVA have?
As of FY2025, Iovance Biotherapeutics, Inc. reported — of total debt against $163M of cash.
What is IOVA's profit margin?
In FY2025, gross margin was 34.3%, operating margin -153.1%, and net margin -148.4%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.